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terventions in general practice. The addition of a disease-
specific HRQoL questionnaire in subjects who are thought
to be likely to have respiratory disease should be considered.
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OBJECTIVES: Chronic obstructive pulmonary disease
(COPD) is a major cause of morbidity and mortality in
Western society and its importance is increasing. The
long-term cost of COPD is currently unknown. The aim
of this study was to estimate the incidence based longi-
tudinal cost of COPD for the UK, from the payer’s per-
spective. METHODS: We examined 160 clinical and epi-
demiological papers and combined selected data in a
Markov model, with a time horizon of 20 years (40
stages of 6 months), and consisting of 29 exclusive health
states, primarily based on the evolution of forced expira-
tory volume in 1 second (FEV1), and history of hospital-
ization. Only sources that defined COPD in line with cur-
rent clinical guidelines were applied. Medical management
was obtained from database information (East of Lon-
don database) and 23 physician interviews. Health state
scores were obtained from a published cross-sectional
survey. Unit costs were obtained from official sources.
Costs are discounted at 6%. Uncertainty was estimated
through Monte Carlo analysis (1,000 runs). RESULTS:
The predicted 20 year cost for a patient starting in a mild
state (FEV1: 60–80%) or a moderate state (FEV1: 40–
59%) is £4,053 (95% CI  £3,743–£4,363) and
£11,746 (95% CI  £11,001–£12,491) respectively. The
cumulative number of Health State Adjusted Life Years is
respectively 12.10 years (95% CI  11.72–12.48) and
7.82 years (95% CI  7.51–8.13) over 20 years. CON-
CLUSIONS: Life expectancy is low, and the costs for pa-
tients starting in mild and moderate states are rather
modest, a finding that supports early diagnosis and inter-
vention. The model may serve as a framework to assess
the health economic impact of current strategies and new
treatment modalities for managing COPD.
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OBJECTIVE: The aim of this study was to compare the
cost-effectiveness of emedastine, a new topical anti-hista-
minic, with topical levocabastine in Belgium, France,
Germany, Netherlands, Norway, Portugal and Sweden,
in the treatment of allergic conjunctivitis. METHODS: A
randomized, controlled, double-masked, multi-country
clinical trial compared the efficacy and safety of emedas-
tine 0.05% bid and levocabastine 0.05% bid. Economic
comparison of a strategy with Emedastine, and a strategy
with Levocabastine, including first line therapy and fail-
ure’s therapy was modelled using clinical trial results and
standard cost approach. Societal perspective was adopted
unless no indirect costs were estimated. Only drug costs
were considered for first line treatment costs. The costs
of failure were established from a panel of Ophthalmolo-
gists and General Practitioners and focused mainly on
out-patient resource utilization: visits, drugs, lab tests,
etc. RESULTS: A total of 221 patients (109 emedastine,
112 levocabastine) presenting with allergic conjunctivitis
were followed over 42 days. From day 7 to day 42, eme-
dastine-treated patients had less itching (P  0.001) and
less redness (P  0.001). The first line treatment failure
rate was 10% less (P  0.02) in emedastine-treated pa-
tients and they had an incremental 8.5 days (P  0.01)
without symptoms. Emedastine was as safe as levocabas-
tine and well tolerated. Emedastine strategy was found
economically dominating relative to levocabastine, i.e.
less costly, and more efficacious, in Germany, Portugal
and Sweden. In France, Belgium, the Netherlands and
Norway less than one € per extra day free of symptoms
has to be paid. Sensitivity analyses were conducted which
confirmed the robustness of our findings. CONCLU-
SION: Based on results of a randomized clinical trial, and
resources and costs associated with failure having been
estimated through expert interviews, our model found
that emedastine is a cost-effective alternative in the treat-
ment of allergic conjunctivitis.
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OBJECTIVE: This literature review identifies quality of
life (QOL), symptom and patient satisfaction (PS) mea-
sures that have been used effectively with adult and pedi-
atric asthma patients in clinical trials. METHODS: A
comprehensive literature review of French or English ar-
ticles, published between 1995 and 1999, was conducted
using Medline, Excerpta Medica and Mapi Research In-
stitute databases. RESULTS: 331 abstracts were assessed
for their relevance to asthma, QOL and PS. For adult
QOL, the literature review identified six generic, ten
asthma-specific, and two respiratory disease specific mea-
sures. A comparison of domains and psychometric prop-
erties yielded 3 generic measures (SIP, NHP, SF-36) and 4
